Stephan Stilgenbauer is Associate Professor and deputy chairman at the Department of Internal Medicine III (Haematology, Oncology, Rheumatology and Infectious Diseases) at Ulm University, Germany.
Stephan received his medical training at Heidelberg Medical School and was trained in internal medicine and haematology-oncology at the Universities of Heidelberg and Ulm. He spent a postdoctoral fellowship at the German Cancer Research Center (DKFZ) in Heidelberg.
Stephan’s research focus is on the molecular pathogenesis and translation into novel treatment strategies in hematological malignancies.
Dr Stilgenbauer has authored or coauthored numerous book chapters and original articles/reviews in journals such as the New England Journal of Medicine, The Lancet, Nature Medicine, PNAS, Journal of Clinical Oncology, Blood, Leukemia and Haematologica.
The Chronic Lymphocytic Leukaemia Knowledge Centre is peer reviewed by Stephan Stilgenbauer. Newer therapies include those targeting the B-cell receptor (BCR) signalling pathway, BCL-2 inhibitors, immunomodulators and chimeric antigen receptors (CARs).
Discussing Chronic Lymphocytic Leukaemia (CLL) including clonal proliferation and accumulation of CD5+CD23+ B-cells, signalling mechanisms, genetic aberrations in 13q14, 11q22-q23 and 17p13, trisomy 12, diagnosis and treatment options.
Alternatively login via
Back to epgonline.org